Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25. The market reaction suggests investors are pricing in concerns over decelerating growth momentum relative to recent quarters and the modest nature of the raised full-year guidance.

The company’s performance was driven by strong demand across its core segments. Revenue from the Diagnostics segment reached $289.3 million, up 20% year-over-year, while Data and Applications revenue grew 28% year-over-year to $93.2 million. Oncology volume growth accelerated by 31% year-over-year, and Data Licensing & Modeling revenue surged 36% year-over-year. Tempus CEO Eric Lefkofsky attributed the results to investments in AI driving growth in the company’s two largest businesses: Oncology Diagnostics and Data Licensing.

Financial Performance Breakdown

Beyond organic growth, Tempus secured approximately $200 million in new data and applications licenses during the quarter. This contract inflow supports the trajectory of its high-margin data business, which continues to expand faster than the diagnostics segment.

Forward Guidance and Market Reaction

Tempus raised its full-year revenue guidance from a prior range of $1.59 billion to $1.60 billion to a new range of $1.595 billion to $1.605 billion. This adjustment implies approximately 25% year-over-year growth for the full year. Adjusted EBITDA is guided at around $65 million. Notably, this guidance excludes any impact from the pending acquisition of Personalis, which is expected to close in late fourth quarter of 2026 or early 2027.

Technical Outlook and Key Levels

From a longer-term trend perspective, TEM is in a downtrend, trading 15.1% below the 20-day SMA, 14.9% below the 50-day SMA, 13.5% below the 100-day SMA, and 26.9% below the 200-day SMA. Momentum indicators show MACD below its signal line with a negative histogram, pointing to fading upside pressure. The 50-day SMA remains below the 200-day SMA, a death cross that occurred in January, keeping intermediate-term trend traders cautious. With the stock down 23.40% over the past 12 months, key resistance sits at $51.00 near the 50-day SMA area, while support is located at $42.50.

What the Numbers Show

The divergence between the earnings beat and the stock price decline highlights investor sensitivity to growth rates rather than absolute profitability metrics. While the company beat estimates, the 22% revenue growth represents a moderation compared to prior periods, leading the market to interpret the minimal upward revision in guidance as a signal of potential slowdown in the latter half of the year. The acquisition of Personalis remains a key variable for future scale, but its exclusion from current guidance leaves near-term growth dependent on existing operations.

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion. This revision places the midpoint of the new guidance above the consensus market estimate of $1.593 billion, indicating that management expects stronger-than-anticipated performance for the fiscal year.

The upward revision underscores the accelerating adoption of Tempus’s data and analytics platform across clinical and commercial settings. By lifting the top end of its guidance range by $50 million, the company highlights improved visibility into its near-term revenue streams. The new outlook suggests that recent product enhancements or expanded partnerships are driving higher engagement with healthcare providers and pharmaceutical clients.

Updated Financial Outlook

The following table details the change in Tempus AI’s fiscal year 2026 sales guidance compared to prior expectations and market estimates.

What the Numbers Show

The decision to raise both the floor and ceiling of the sales range demonstrates a broad-based improvement in business fundamentals rather than a narrow adjustment at the margins. With the new midpoint of $1.600 billion surpassing the $1.593 billion analyst estimate, Tempus AI is positioning itself as a leader in the AI-healthcare intersection. Investors should note that this guidance increase reflects operational momentum, suggesting that the company’s strategic initiatives are effectively converting into tangible revenue growth ahead of schedule.